Alembic Pharmaceuticals has informed the exchange that the Company's joint venture, Aleor Dermaceuticals, has received US Food and Drug Administration (USFDA) Final Approval for Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram. In this regard, the company has enclosed its press release on 1st April, 2021.
The above information is a part of company’s filings submitted to BSE.